Abstract: The Food and Drug Administration has approved anti-CD19 chimeric antigen receptor T cells, namely axicabtagene ciloleucel and tisagenlecleucel, for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, this therapy is associated with a series of toxicities (acute and late) and rare adverse events. Acute toxicities mainly comprise cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hemophagocytic syndrome, whereas long-term toxicities include cytopenia, B-cell aplasia, and hypogammaglobulinemia. This review will mainly discuss the pathogenesis, clinical manifestations, classification and management, risk factors, and prophylactic measures of the two most common toxicities CRS and ICANS. In addition, late toxicities and rare adverse events will be reviewed.